{"id":83618,"topic":"peptides","source":"TradingView","title":"凯莱英(002821.SZ)：当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市 - TradingView","url":"https://www.tradingview.com/news/gelonghui:10daed57fe3f9:0/","url_hash":"ff6242d000177b47fdd34afb7588f02496625823","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMia0FVX3lxTE5VRUdjSzFOWTFaQWRNckhWM1pTN2tJRW1MSDZXcTAwaDJ2YkFkdmNONzFyMU9lWUdHS1V6N1RSdEtlU0NMdVUzT0ZuWkVOdnFmSUkyZnM5bW1oYXNwLUkxYnk5azhlaml4czhz?oc=5\" target=\"_blank\">凯莱英(002821.SZ)：当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TradingView</font>","content":"凯莱英(002821.SZ)：当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市\n格隆汇9月3日丨凯莱英002821在投资者关系活动上表示，目前建设的多肽产能以商业化产能为主，满产需一定周期爬坡。当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市，验证批（PPQ）与商业化备货预计2027年开始。据此，商业化产能满产尚需时间爬坡；产能陆续爬坡后，多肽业务盈利能力将显著改善。生物大分子CDMO商业化生产基地，一期已全面投产并进入验证批（PPQ）生产阶段；今年启动二期扩建，其中包括ADC的（原液）DS环节增加非高活产线；后续随着产能爬坡将显现规模化效应。在爬坡阶段我们也会通过持续提高效率来改善毛利率表现。","image_url":"https://static.tradingview.com/static/images/logo-preview.png","lang":"zh","published_at":"2026-09-03T07:00:00+00:00","fetched_at":"2026-09-16T08:15:12+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"凯莱英(002821.SZ)：当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市\n格隆汇9月3日丨凯莱英002821在投资者关系活动上表示，目前建设的多肽产能以商业化产能为主，满产需一定周期爬坡。当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市，验证批（PPQ）与商业化备货预计2027年开始。据此，商业化产能满产尚需时间爬坡；产能陆续爬坡后，多肽业务盈利能力将显著改善。生物大分子CDMO商业化生产基地，…","cluster_id":null,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://www.tradingview.com/news/gelonghui:10daed57fe3f9:0/","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 319 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":319,"summary_length":221,"usable_text_length":319,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":319,"summary_length":221}},"news_item":{"id":83618,"canonical_url":"https://www.tradingview.com/news/gelonghui:10daed57fe3f9:0/","source_url":"https://www.tradingview.com/news/gelonghui:10daed57fe3f9:0/","title":"凯莱英(002821.SZ)：当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市 - TradingView","source_name":"TradingView","author":null,"published_at":"2026-09-03T07:00:00+00:00","locale":"zh","topic":"peptides","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMia0FVX3lxTE5VRUdjSzFOWTFaQWRNckhWM1pTN2tJRW1MSDZXcTAwaDJ2YkFkdmNONzFyMU9lWUdHS1V6N1RSdEtlU0NMdVUzT0ZuWkVOdnFmSUkyZnM5bW1oYXNwLUkxYnk5azhlaml4czhz?oc=5\" target=\"_blank\">凯莱英(002821.SZ)：当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TradingView</font>","full_text":"凯莱英(002821.SZ)：当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市\n格隆汇9月3日丨凯莱英002821在投资者关系活动上表示，目前建设的多肽产能以商业化产能为主，满产需一定周期爬坡。当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市，验证批（PPQ）与商业化备货预计2027年开始。据此，商业化产能满产尚需时间爬坡；产能陆续爬坡后，多肽业务盈利能力将显著改善。生物大分子CDMO商业化生产基地，一期已全面投产并进入验证批（PPQ）生产阶段；今年启动二期扩建，其中包括ADC的（原液）DS环节增加非高活产线；后续随着产能爬坡将显现规模化效应。在爬坡阶段我们也会通过持续提高效率来改善毛利率表现。","excerpt":"凯莱英(002821.SZ)：当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市\n格隆汇9月3日丨凯莱英002821在投资者关系活动上表示，目前建设的多肽产能以商业化产能为主，满产需一定周期爬坡。当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市，验证批（PPQ）与商业化备货预计2027年开始。据此，商业化产能满产尚需时间爬坡；产能陆续爬坡后，多肽业务盈利能力将显著改善。生物大分子CDMO商业化生产基地，…","extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 319 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.tradingview.com/news/gelonghui%3A10daed57fe3f9%3A0/","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 319 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":319,"summary_length":221,"usable_text_length":319,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":319,"summary_length":221}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"凯莱英(002821.SZ)：当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市 - TradingView","url":"https://www.tradingview.com/news/gelonghui:10daed57fe3f9:0/","summary":"凯莱英(002821.SZ)：当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市\n格隆汇9月3日丨凯莱英002821在投资者关系活动上表示，目前建设的多肽产能以商业化产能为主，满产需一定周期爬坡。当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市，验证批（PPQ）与商业化备货预计2027年开始。据此，商业化产能满产尚需时间爬坡；产能陆续爬坡后，多肽业务盈利能力将显著改善。生物大分子CDMO商业化生产基地，…","source":"TradingView","date":"2026-09-03T07:00:00+00:00","content":"凯莱英(002821.SZ)：当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市\n格隆汇9月3日丨凯莱英002821在投资者关系活动上表示，目前建设的多肽产能以商业化产能为主，满产需一定周期爬坡。当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市，验证批（PPQ）与商业化备货预计2027年开始。据此，商业化产能满产尚需时间爬坡；产能陆续爬坡后，多肽业务盈利能力将显著改善。生物大分子CDMO商业化生产基地，一期已全面投产并进入验证批（PPQ）生产阶段；今年启动二期扩建，其中包括ADC的（原液）DS环节增加非高活产线；后续随着产能爬坡将显现规模化效应。在爬坡阶段我们也会通过持续提高效率来改善毛利率表现。","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.tradingview.com/news/gelonghui%3A10daed57fe3f9%3A0/","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 319 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 319 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":319,"summary_length":221,"usable_text_length":319,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":319,"summary_length":221}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/83618","export_markdown":"/api/items/83618/export?format=markdown","export_json":"/api/items/83618/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.tradingview.com/news/gelonghui%3A10daed57fe3f9%3A0/"},"formats":{"full":{"id":83618,"title":"凯莱英(002821.SZ)：当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市 - TradingView","url":"https://www.tradingview.com/news/gelonghui:10daed57fe3f9:0/","source":"TradingView","author":null,"published_at":"2026-09-03T07:00:00+00:00","locale":"zh","topic":"peptides","tags":[],"excerpt":"凯莱英(002821.SZ)：当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市\n格隆汇9月3日丨凯莱英002821在投资者关系活动上表示，目前建设的多肽产能以商业化产能为主，满产需一定周期爬坡。当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市，验证批（PPQ）与商业化备货预计2027年开始。据此，商业化产能满产尚需时间爬坡；产能陆续爬坡后，多肽业务盈利能力将显著改善。生物大分子CDMO商业化生产基地，…","full_text":"凯莱英(002821.SZ)：当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市\n格隆汇9月3日丨凯莱英002821在投资者关系活动上表示，目前建设的多肽产能以商业化产能为主，满产需一定周期爬坡。当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市，验证批（PPQ）与商业化备货预计2027年开始。据此，商业化产能满产尚需时间爬坡；产能陆续爬坡后，多肽业务盈利能力将显著改善。生物大分子CDMO商业化生产基地，一期已全面投产并进入验证批（PPQ）生产阶段；今年启动二期扩建，其中包括ADC的（原液）DS环节增加非高活产线；后续随着产能爬坡将显现规模化效应。在爬坡阶段我们也会通过持续提高效率来改善毛利率表现。","reading_time_min":1,"extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 319 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.tradingview.com/news/gelonghui%3A10daed57fe3f9%3A0/","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 319 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":319,"summary_length":221,"usable_text_length":319,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":319,"summary_length":221}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 319 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":319,"summary_length":221,"usable_text_length":319,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":319,"summary_length":221}},"actions":{"read":"/item/83618","export_markdown":"/api/items/83618/export?format=markdown","export_json":"/api/items/83618/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.tradingview.com/news/gelonghui%3A10daed57fe3f9%3A0/"}},"digest":{"id":83618,"title":"凯莱英(002821.SZ)：当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市 - TradingView","url":"https://www.tradingview.com/news/gelonghui:10daed57fe3f9:0/","source":"TradingView","topic":"peptides","published_at":"2026-09-03T07:00:00+00:00","excerpt":"凯莱英(002821.SZ)：当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市 格隆汇9月3日丨凯莱英002821在投资者关系活动上表示，目前建设的多肽产能以商业化产能为主，满产需一定周期爬坡。当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市，验证批（PPQ）与商业化备货预计2027年开始。据此，商业化产能满产尚需时间爬坡；产能陆续爬坡后，多肽业务盈利能力将显著改善。生物大分子CDMO商业化生产基地，…","quality_bucket":"high","quality_reason":"High confidence: full text extraction produced 319 characters.","reading_time_min":1,"cluster_id":null},"card":{"display_title":"凯莱英(002821.SZ)：当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市 - TradingView","subtitle":"TradingView · 2026-09-03","summary":"凯莱英(002821.SZ)：当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市…","badges":["quality:high"],"links":{"read":"/item/83618","original":"https://www.tradingview.com/news/gelonghui:10daed57fe3f9:0/","diagnose":"/api/diagnose?url=https%3A//www.tradingview.com/news/gelonghui%3A10daed57fe3f9%3A0/"},"quality_warning":null},"export":{"title":"凯莱英(002821.SZ)：当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市 - TradingView","url":"https://www.tradingview.com/news/gelonghui:10daed57fe3f9:0/","summary":"凯莱英(002821.SZ)：当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市\n格隆汇9月3日丨凯莱英002821在投资者关系活动上表示，目前建设的多肽产能以商业化产能为主，满产需一定周期爬坡。当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市，验证批（PPQ）与商业化备货预计2027年开始。据此，商业化产能满产尚需时间爬坡；产能陆续爬坡后，多肽业务盈利能力将显著改善。生物大分子CDMO商业化生产基地，…","source":"TradingView","date":"2026-09-03T07:00:00+00:00","content":"凯莱英(002821.SZ)：当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市\n格隆汇9月3日丨凯莱英002821在投资者关系活动上表示，目前建设的多肽产能以商业化产能为主，满产需一定周期爬坡。当前在服务一个商业化多肽项目，其余项目预计2028年起陆续推进上市，验证批（PPQ）与商业化备货预计2027年开始。据此，商业化产能满产尚需时间爬坡；产能陆续爬坡后，多肽业务盈利能力将显著改善。生物大分子CDMO商业化生产基地，一期已全面投产并进入验证批（PPQ）生产阶段；今年启动二期扩建，其中包括ADC的（原液）DS环节增加非高活产线；后续随着产能爬坡将显现规模化效应。在爬坡阶段我们也会通过持续提高效率来改善毛利率表现。","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.tradingview.com/news/gelonghui%3A10daed57fe3f9%3A0/","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 319 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 319 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":319,"summary_length":221,"usable_text_length":319,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":319,"summary_length":221}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}